Ingredients

Urolithin A vs NMN: Evidence & Mechanism Differences

Written by ReCellence™ Editorial Team, Health Content SpecialistsReviewed by Medical Review Board, MD, PhDLast reviewed: March 7, 2026

Medical Disclaimer: This content is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before making any health-related decisions. If you are experiencing a medical emergency, call your local emergency services immediately.

What Each Is

Urolithin A

Dietary Supplement

Urolithin A is a gut-derived postbiotic that activates the PINK1/Parkin mitophagy pathway, selectively recycling damaged mitochondria. FDA GRAS status. 8–10 published human trials focused on muscle endurance and mitochondrial biomarkers.

NMN

Dietary Supplement

NMN (nicotinamide mononucleotide) is a direct precursor to NAD+, a coenzyme essential for hundreds of metabolic reactions including sirtuin activity. NAD+ declines ~50% between ages 40 and 60. NMN regulatory status is complex (FDA questioned its supplement status in 2022).

Evidence Type Comparison

Understanding the difference in evidence quality between these options.

AspectUrolithin ANMN
FDA StatusFDA GRAS status (2018)Questionable supplement status (FDA 2022)
Primary MechanismPINK1/Parkin mitophagy activationNAD+ precursor (restores declining levels)
Human Evidence Stage8–10 published trialsSeveral human trials (250–1250 mg/day)
Strongest EvidenceMuscle endurance, mitochondrial biomarkersNAD+ elevation, insulin sensitivity (preliminary)
Dosing500–1000 mg/day250–1250 mg/day
Regulatory StatusClear (GRAS)Disputed (drug investigation concurrent)

Mechanism Hypotheses (Conceptual)

Note: Mechanism hypotheses describe how compounds are thought to work based on laboratory research. This does not confirm clinical benefit or efficacy in humans.

Urolithin A

UA activates the PINK1/Parkin mitophagy pathway, selectively removing damaged mitochondria and allowing cells to replace them with healthier ones.

NMN

NMN is converted to NAD+ in cells. NAD+ is essential for sirtuin activity (deacetylases that regulate mitochondrial function, DNA repair, and metabolism) and hundreds of redox reactions. Restoring age-declined NAD+ aims to support these processes.

Critical difference: UA and NMN target different but potentially related aspects of cellular aging. UA clears damaged mitochondria; NMN fuels the remaining healthy ones via NAD+. The theoretical complementarity has not been tested in any published human study.

Safety & Tolerability Patterns

Urolithin A

Tested at up to 2000 mg/day for 28 days and 1000 mg/day for 4 months. Safety profile similar to placebo. Mild GI symptoms most common.

NMN

Studied at 250–1250 mg/day in several human trials, generally showing good tolerability. Regulatory status is complex — FDA questioned its classification as a dietary supplement since Metro International Biotech is investigating NMN as a drug candidate. No comprehensive long-term safety data.

Key difference: UA has clear regulatory status (GRAS). NMN's regulatory status is disputed, affecting availability and consumer certainty. Both lack comprehensive long-term safety data.

Drug Interaction Considerations

NMN's drug interaction profile is not well-characterized. UA has no reported specific drug interactions but comprehensive studies are lacking. Always discuss any supplements with your pharmacist, especially if you take prescription medications.

Always discuss any supplements with your pharmacist, especially if you take prescription medications.

Decision Factors to Discuss Clinically

These factors should be discussed with your healthcare provider—not decided based on online information alone:

  • •Current medications and potential interactions
  • •Other health conditions (comorbidities)
  • •Symptom severity and impact on quality of life
  • •Your goals and preferences for treatment approach
  • •How you'll objectively track symptom changes (e.g., IPSS scores)

Questions to Bring to Your Appointment

Discussing supplements with your healthcare provider

1

Between these supplements, which has the most evidence for prostate symptoms?

Comparing DIM to saw palmetto, beta-sitosterol, etc.

2

Could combining supplements increase side effect risk?

Understanding multi-ingredient formulas

3

How do I choose a quality supplement product?

Third-party testing, standardization, reputable brands

4

What's a reasonable trial period before deciding if a supplement works?

Timeline for evaluation

5

At what point should I consider prescription options instead?

Knowing when supplements aren't enough

Tip: Write down these questions before your appointment. Bring a list of all current medications and supplements you take, including dosages. Consider asking about objective symptom tracking to measure changes over time.

Quick Answers

Q1.

Is Urolithin A better than NMN?

Neither is proven "better" — they target different pathways. UA activates mitophagy (clearing damaged mitochondria); NMN restores NAD+ levels. No head-to-head trial exists. Both have early-stage human evidence for different outcomes.

Q2.

Can you take Urolithin A and NMN together?

Combining them has not been studied. Theoretically complementary (UA clears damaged mitochondria, NMN fuels healthy ones via NAD+), but no published trial tests this combination. Consult a healthcare provider.

Q3.

Is NMN FDA approved?

No. The FDA issued a warning letter in 2022 questioning NMN's status as a dietary supplement due to its concurrent investigation as a drug by Metro International Biotech. Its regulatory status remains disputed, unlike UA which has clear GRAS status.

Q4.

Does NMN activate mitophagy like Urolithin A?

No. NMN is a NAD+ precursor — it restores NAD+ levels that decline with age. UA directly activates the PINK1/Parkin mitophagy pathway. Different mechanisms, though both relate to mitochondrial health.

Q5.

Which raises NAD+ levels — Urolithin A or NMN?

NMN. NMN is a direct NAD+ precursor that has been shown to increase blood NAD+ levels by ~38% at 250 mg/day for 12 weeks. UA does not directly raise NAD+ levels — it activates mitophagy through a different pathway.

Q6.

How much NMN do you need per day?

Published human trials used 250–1250 mg/day. The Yoshino 2021 trial used 250 mg/day for 12 weeks and increased blood NAD+ by ~38%. Optimal dosing has not been established.

Q7.

Is NMN the same as NR (nicotinamide riboside)?

No. Both are NAD+ precursors but distinct compounds. NR has clearer US regulatory status and similar clinical evidence for NAD+ elevation. NMN's regulatory status is disputed; NR is generally available as a supplement.

Q8.

Which has more human clinical trials?

NMN has several published human trials (pharmacokinetics and metabolic parameters). UA has approximately 8–10 published trials (muscle endurance and mitochondrial biomarkers). Both have early-stage evidence bases.

Q9.

Does NMN improve muscle function?

NMN improved insulin sensitivity in skeletal muscle of overweight women (n=25) but did not significantly change other metabolic markers. UA has stronger direct evidence for muscle endurance improvements (12–17% in JAMA trial).

Q10.

Are Urolithin A and NMN safe long-term?

Neither has comprehensive long-term safety data. UA's longest trial was 4 months. NMN has been studied up to 12 weeks in published trials. Both showed good short-term tolerability. Long-term safety is unknown for both.

Q11.

Can NMN reverse aging?

No human evidence supports NMN reversing aging. NAD+ declines with age, and NMN restores levels, but whether this translates to anti-aging effects in humans is unproven. Preclinical models show age-related functional improvements, but human data is early-stage.

Q12.

Which is more expensive, Urolithin A or NMN?

Both are premium supplements. NMN cost varies widely and is affected by its disputed regulatory status. UA (Mitopure®) is patented with higher cost reflecting clinical trial investment. Prices are comparable in the premium supplement range.

Q13.

Does NMN need gut bacteria like Urolithin A?

No. NMN is absorbed directly as a NAD+ precursor. UA is produced by gut bacteria metabolizing ellagitannins — only ~40% of people efficiently produce it. Direct UA supplementation bypasses this gut dependency.

Q14.

What is the difference between mitophagy and NAD+ boosting?

Mitophagy (UA) is the selective removal of damaged mitochondria. NAD+ boosting (NMN) restores a coenzyme essential for energy metabolism and sirtuin activity. One clears damaged components; the other fuels metabolic processes.

Q15.

Should I take NMN or Urolithin A for energy?

No head-to-head comparison exists. UA has direct evidence for muscle endurance and mitochondrial biomarker improvements. NMN raises NAD+ but direct energy/energy benefits in humans are less established. Discuss with your healthcare provider.

Key Research Facts

1

NMN supplementation at 250 mg/day for 12 weeks increased blood NAD+ levels by ~38% in overweight adults (n=25).

Strong Evidence

Yoshino et al., Science — doi:10.1126/science.abe9985

2

Urolithin A activated the PINK1/Parkin mitophagy pathway and extended C. elegans lifespan by 45% in the landmark 2016 study.

Strong Evidence

Ryu et al., Nature Medicine — doi:10.1038/nm.4132

3

The FDA issued a warning letter in 2022 questioning NMN's status as a dietary supplement due to its concurrent investigation as a drug by Metro International Biotech.

Strong Evidence

FDA regulatory filing — FDA-2022-N-2860

4

NAD+ levels decline approximately 50% between ages 40 and 60 in human tissues, providing the rationale for NMN supplementation.

Strong Evidence

Imai & Guarente, Trends Cell Biol — doi:10.1016/j.tcb.2014.12.002

5

Both UA (1000 mg/day × 4 months) and NMN (250–1250 mg/day × 12 weeks) were well-tolerated with adverse events similar to placebo in published trials.

Strong Evidence

Andreux et al., 2019; Yoshino et al., 2021 — Multiple DOIs

6

No published clinical trial has compared Urolithin A and NMN directly for any outcome.

Strong Evidence

ClinicalTrials.gov search — Accessed March 2026

7

NMN improved insulin sensitivity in skeletal muscle of overweight women (n=25) but did not change other metabolic markers significantly.

Moderate Evidence

Yoshino et al., Science — doi:10.1126/science.abe9985

8

UA's human evidence is concentrated on muscle endurance and mitochondrial biomarkers, while NMN trials primarily measure NAD+ pharmacokinetics and metabolic parameters.

Moderate Evidence

Comparative literature review — PubMed analysis, 2026

9

Nicotinamide Riboside (NR), a related NAD+ precursor, has clearer US regulatory status than NMN and similar clinical evidence for NAD+ elevation.

Moderate Evidence

Martens et al., Nature Communications — doi:10.1038/s41467-018-03421-7

10

Preclinical studies suggest UA and NAD+ precursors may be complementary — addressing mitochondrial quality (UA) and metabolic cofactor availability (NMN) — but this has not been tested in humans.

Emerging Evidence

Theoretical framework — D'Amico et al., 2021; Imai, 2014

Continue Your Research

Explore related topics and take the next step in your cellular health journey.

Related Comparisons

Explore more head-to-head supplement comparisons backed by clinical evidence.

Citations & External Resources

Clinical Registry

ClinicalTrials.gov — Search: NMN

Clinical Registry

ClinicalTrials.gov — Search: Urolithin A

Review

Science — Yoshino et al. 2021 (NMN in Overweight Women)

Review

Nature Medicine — Ryu et al. 2016 (UA Landmark Study)

Review

PubMed — NMN human trials

Regulatory

FDA Regulatory Notice on NMN Status

Review

JAMA Network Open — Liu et al. 2022 (UA Muscle Endurance)

Related Reading

References (3)

Written by

ReCellence™ Editorial Team

Health Content Specialists

Medically reviewed by

Medical Review Board

MD, PhD

Last updated: March 8, 2026

Last medical review: March 8, 2026